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OBJECTIVES The role of P-selectin in the process of restenosis was evaluated using a recombinant
immunoglobulin (Ig) chimera form of its ligand, soluble P-selectin glycoprotein ligand-Ig
(rPSGL-Ig), as a competitive inhibitor for the natural ligand on leukocytes.
BACKGROUND Inflammation and coagulation activation after vascular injury may be an important factor in
the development of restenosis. P-selectin has been shown to mediate leukocyte-endothelium
and leukocyte-platelet interaction. These interactions are mediated through binding of
P-selectin to P-selectin glycoprotein ligand-1 (PSGL-1) located on the surface of leukocytes.
METHODS Balloon injury was induced in the left anterior descending and right coronary arteries of 16
pigs at a balloon/artery diameter ratio of 1.5:1. Either rPSGL-Ig (1 mg/kg) or saline was
randomly administered 15 min before balloon injury as an intravenous bolus. Four weeks after
injury, morphometric analysis, immunohistochemistry and histological evaluation were
performed on injured arterial segments.
RESULTS Increased luminal area was found in the rPSGL-Ig group compared with the placebo group
(1.63 6 0.57 mm2 vs. 1.26 6 0.32 mm2, p 5 0.044) owing to significantly reduced
neointimal hyperplasia (cross-sectional area, 0.46 6 0.45 mm2 vs. 0.13 6 0.11 mm2, p 5
0.013). Immunohistochemistry and histological evaluation showed a significant decrease in
the presence of tumor necrosis factor-alpha, interleukin-1 beta, and infiltration of macro-
phages in the injured vessel segments in the rPSGL-Lg group.
CONCLUSIONS P-selectin antagonism using rPSGL-Ig decreases neointimal hyperplasia following balloon
injury, by inhibiting the inflammatory and thrombotic responses at the site of balloon injury,
which appears to play a pivotal role in the pathogenesis of restenosis. (J Am Coll Cardiol
2001;38:577–82) © 2001 by the American College of Cardiology
Restenosis remains the major limitation of percutaneous
transluminal intervention. Recently, it has been recognized
that local inflammatory and thrombotic reactions including
platelet/leukocyte and leukocyte/endothelial cell complex
formation induced by vessel injury due to balloon angio-
plasty play an important role in this complex process (1–5).
This recruitment of inflammatory cells results in the release
of growth factors and cytokines, which induce smooth
muscle cell (SMC) migration and proliferation. This local
leukocyte/platelet response is mediated by a group of com-
plementary cell adhesion molecules, which consists of three
families: the selectins, the integrins, and the immunoglobulin
supergene family. Selectins, a family of calcium-dependent
lectins including P-, L- and E-selectins, are known to be very
important in leukocyte and platelet adhesion to the endothe-
lium, with P-selectin mediating the initial response. P-selectin
is stored in alpha granules of platelets and Weibel-Palade
bodies of endothelial cells and is rapidly translocated to the
platelet and endothelial cell surface after cell activation.
P-selectin promotes rolling of circulating leukocytes on the
endothelium and positions them for activation. In addition,
P-selectin induces leukocyte-leukocyte and leukocyte-platelet
interaction. These interactions are mediated through the bind-
ing of P-selectin to P-selectin glycoprotein ligand-1 (PSGL-1)
located on the surface of leukocytes.
The rPSGL-Ig is a recombinant immunoglobulin chi-
mera form of PSGL-1; it inhibits P-selectin–mediated
platelet-neutrophil adhesion by acting as a competitive
inhibitor for PSGL-1 on leukocytes. It has been recently
shown that antagonism of P-selectin reduced the throm-
botic and inflammatory response and resulted in increased
luminal diameter after balloon injury in the rat and porcine
carotid artery models (6–8). In a recent study (9), our group
demonstrated that administration of rPSGL-Ig competi-
tively binds P-selectin, decreases the degree of inflammatory
response and attenuates the selectin-mediated endothelial
dysfunction and myocardial injury following reperfusion of
ischemic myocardium. In the current study, the effect of
rPSGL-Ig on neointimal hyperplasia after balloon injury in
the porcine coronary artery model was assessed.
METHODS
rPSGL-Ig. PSGL-1 is the natural ligand for P-selectin
and binds P-selectin via an anionic amino-terminal peptide
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sequence. Also, PSGL-1 appears to account for all of the
high-affinity P-selectin binding sites on neutrophils (10,11).
rPSGL-Ig, a recombinant immunoglobulin chimera form
of PSGL-1, is produced in Chinese hamster ovary cells,
which have been engineered to co-express the critical
carbohydrate-modifying enzymes fucosyltransferase VII and
core2 GlcNAc transferase. It consists of the first 47 amino
acids from the N-terminal end of the extracellular domain
of mature PSGL-1, fused at the “hinge” region to human
IgG1. Two “hinge-proximal” amino acids at positions 234
and 237 within the IgGFc portion are mutated to alanine to
reduce both complement activation and Fc receptor bind-
ing. This manipulation of the compound gives it a long
half-life, ’11 days in pigs (unpublished data) and also
maintains the bivalent presentation of the native molecule as
well as high P-selectin affinity and reduced L-selectin and
E-selectin binding.
Animal preparation. Juvenile domestic farm pigs weighing
22 to 25 kg were treated with 325 mg of aspirin orally one
day before surgery through 28 days follow-up. General
anesthesia was induced by intramuscular injection of ket-
amine 22 mg/kg and maintained with inhaled isoflurane.
The carotid artery and jugular vein were dissected from
surrounding tissue through a midline cervical incision. An
8F sheath was introduced into the carotid artery over a
guide wire, and a heparin bolus of 300 IU/kg was admin-
istered. Either rPSGL-Ig (1 mg/kg) or saline was randomly
administered 15 min before balloon injury as an intravenous
(IV) bolus.
Following baseline coronary angiography, balloon injury
was performed to one segment each of the right coronary
artery (RCA) and left anterior descending coronary artery
(LAD) of each animal, based on the angiographic estima-
tion of vessel diameter and a balloon/artery ratio of 1.5:1.
Three inflations were made at a pressure of 8 atm for 30 s
at 1-min intervals. Following arterial injury, coronary an-
giography was repeated to confirm vessel patency. The
carotid artery was repaired or ligated. The wound was closed
with layered interrupted sutures. Animals were treated with
prophylactic antibiotics and acetaminophen for postopera-
tive pain. Throughout the study period all animals were fed
a standard laboratory diet.
After 28 days, follow-up angiography was performed
using the same method as described above. Following
angiography, animals were euthanized with an overdose of
IV sodium pentobarbital and potassium chloride. All exper-
iments conformed to the position of the American Heart
Association on research animal use and care and were
conducted with the approval of the Animal Research
Committee of the Cleveland Clinic Foundation.
Histological analysis and morphometry. The animal
heart was removed immediately after death and perfusion-
fixed with HistoCHOICE™ (AMRESCO Inc., Solon,
Ohio) at 70 mm Hg for 4 h. Injured arterial segments were
located based on their angiographic relationship to side
branches and then removed. These segments were sectioned
at 2-mm intervals perpendicular to the vessel long axis.
Each segment was embedded in paraffin blocks, sectioned
and stained with hematoxylin-eosin and Movat penta-
chrome. Quantitative measurements were performed by an
observer blinded to the treatment regimen, using comput-
erized digital microscopic planimetry software (Image-Pro
Plus, Version 4.0 for Windows, Media Cybernetics, Silver
Spring, Maryland). Morphometric parameters were mea-
sured in four to six sections of injured arterial segments per
vessel and averaged. The fracture length (FL) of internal
elastic lamina (IEL) was measured. The ratio of neointimal
area/fracture length of IEL (IA/FL) was applied to provide
the normalized value of intimal area related to the extent of
vessel injury.
Immunohistochemical assay. Immunohistochemical anal-
ysis was performed to determine the extent of inflammation
and SMC proliferation and to assess for the presence of the
cytokines interleukin-1 beta (IL-1 beta) and tumor necrosis
factor-alpha (TNF-alpha). The following antibodies were
used in this study; anti-proliferating cell nuclear antigen
(PCNA) (Dako, Carpinteria, California), anti-fibronectin
(Dako, California), anti-IL-1 beta (R&D System, Minne-
apolis, Minnesota), and anti-TNF-alpha (R&D System).
As described before (4), the amount of each antigen in the
samples was assessed semiquantitatively by an independent
observer. Immunohistochemical staining was performed
using a Jung Histostainer (Leica, Chicago, Illinois), with
processing occuring at 30°C. A 1% hydrogen peroxide
solution in methanol for 5 min was used to remove any
endogenous peroxidase present in the tissue section.
For mouse monoclonal primary antibodies, a blocking
solution comprising a 1:10 dilution of normal rabbit serum
(Dako) in phosphate-buffered saline (PBS) was added for
10 min before application of the primary antibody. The
required dilutions of antibody were prepared using 1%
bovine serum albumin (BSA) in PBS. Incubation occurred
at 30°C for 60 min, and a 1:200 dilution of biotinylated
rabbit anti-mouse polyclonal antibody (Dako) was added for
Abbreviations and Acronyms
BSA 5 bovine serum albumin
FL 5 fracture length
IA/FL 5 ratio of neointimal area/fracture length of
the internal elastic lamina
IEL 5 internal elastic lamina
IL-1 beta 5 interleukin-1 beta
IV 5 intravenous
LAD 5 left anterior descending coronary artery
NO 5 nitric oxide
PBS 5 phosphate-buffered saline
PCNA 5 proliferating cell nuclear antigen
PSGL-1 5 P-selectin glycoprotein ligand-1
RCA 5 right coronary artery
rPSGL-Ig 5 recombinant P-selectin glycoprotein
ligand-immunoglobulin
SMC 5 smooth muscle cell
TNF-alpha 5 tumor necrosis factor-alpha
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a further 30 min. The antibody was labeled using an Elite
avidin/biotin/peroxidase complex (Vector Laboratories,
Burlingame, California) applied for 30 min. Then 3,3-
diaminobenzidine was added as a chromogen (DAB Kit,
Vector Laboratories).
For polyclonal antibodies, a similar procedure was fol-
lowed, except that normal swine serum instead of rabbit
serum was used as a blocking agent and biotinylated swine
anti-rabbit polyclonal antibody was used as the link. Fol-
lowing staining, the sections were counterstained with
hematoxylin, dehydrated and cleared in xylene. The nega-
tive control sections were treated in an identical manner to
the test tissue, except that 1% BSA in PBS was added
instead of primary antibody.
Statistical analysis. Statistical analysis was performed us-
ing SPSS software (Version 7.0 for Windows, SPSS,
Chicago, Illinois). Data are presented as mean 6 SD.
Continuous variables were compared using unpaired t tests.
A value of p # 0.05 is considered to be statistically
significant.
RESULTS
A total of 19 animals underwent balloon injury (9 in the
rPSGL-Ig group, 10 in the control group). Two of them
died during the procedure due to ventricular fibrillation (one
in the control group, the other in the rPSGL-Ig group), and
one additional death occurred one day after balloon injury in
the control group. The surviving 16 animals (control
group 5 8; rPSGL-Ig group 5 8) finished the study
without complications, providing 15 lesions for analysis in
the control group (7 in RCA; 8 in LAD) and 15 lesions in
the rPSGL-Ig group (7 in RCA; 8 in LAD).
Histological analysis and morphometry. Qualitative his-
tological examination 28 days after balloon injury showed
that less macrophage infiltration occurred in the rPSGL-Ig
group compared with the placebo group (Fig. 1). Quanti-
tative morphometric measurements are summarized in the
Table 1. There were no differences with regard to the extent
of vessel injury (as measured by the extent of FL), IEL and
external elastic lamina areas between treatment arms. How-
ever, treatment with rPSGL-Ig significantly reduced neo-
intimal area by over 70% (0.46 6 0.45 mm2 vs. 0.13 6
0.11 mm2, p 5 0.013), resulting in increased luminal area in
the rPSGL-Ig group compared with the placebo group
(1.63 6 0.57 mm2 vs. 1.26 6 0.32 mm2, p 5 0.044) (Fig.
2). This difference still existed when intimal area was
normalized to the extent of injury (IA/FL, 0.53 6 0.53 vs.
0.16 6 0.13; p 5 0.014).
Immunohistochemistry assay. No qualitative differences
were seen in the appearance of fibronectin staining between
the two groups. In contrast, staining for TNF-alpha, IL-1
beta and PCNA was more evident among animals receiving
placebo instead of rPSGL-Ig (Fig. 3). Only 3 of 15 lesions
from the rPSGL-Ig group showed mild staining for TNF-
alpha, whereas 13 of 15 lesions from the placebo group had
mild-to-moderate degrees of staining (5/15 mild; 8/15
moderate). Similarly, only 5 of 15 lesions from the
rPSGL-Ig group had positive staining for IL-1 beta (4/15
mild; 1/15 moderate), whereas 12 of 15 showed mild-to-
moderate staining (5/15 mild; 7/15 moderate). None of 15
lesions from the rPSGL-Ig group showed the positive
staining of PCNA, whereas 9 of 15 lesions from the placebo
group had mild-to-moderate staining (4/15 mild; 5/15
moderate).
Figure 1. Photomicrographs of cross sections of porcine coronary arteries 28 days after injury (hematoxylin and eosin staining, 203). (A) Representative
light microscopy cross section of injured coronary artery from recombinant P-selectin glycoprotein ligand-immunoglobulin group, showing mild
macrophage infiltration. (B) Representative light microscopy cross section of injured coronary artery from the placebo group, showing extensive macrophage
infiltration.






Luminal area (mm2) 1.26 6 0.32 1.63 6 0.57*
IA (mm2) 0.46 6 0.45 0.13 6 0.11*
IEL area (mm2) 1.72 6 0.48 1.77 6 0.55
Fracture IEL length (mm) 0.86 6 0.12 0.84 6 0.11
Medial area (mm2) 0.72 6 0.21 0.83 6 0.26
EEL area (mm2) 2.44 6 0.59 2.59 6 0.67
IA/FL 0.52 6 0.46 0.16 6 0.13*
*p , 0.05.
EEL 5 external elastic lamina; IA 5 neointimal area; IEL 5 internal elastic
lamina; rPSGL-Ig 5 recombinant P-selectin glycoprotein ligand-immunoglobulin.
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DISCUSSION
We investigated the efficacy of rPSGL-Ig in reducing
restenosis in a porcine coronary artery balloon injury model.
The findings demonstrate that rPSGL-Ig, when used by a
single preprocedural IV bolus, significantly reduces the
extent of neointimal hyperplasia and results in increased
luminal area. Therapy with rPSGL-Ig was also associated
with reduced immunostaining for inflammatory markers
and inflammatory cellular infiltration. The results of this
study highlight the important role of inflammation in the
pathogenesis of restenosis following percutaneous coronary
recanalization in this experimental model.
In the past decade, extensive research has aimed at
reducing restenosis after percutaneous revascularization pro-
cedures. Although the mechanism of restenosis remains
incompletely defined, the role of inflammation and throm-
bosis induced by vessel injury has recently been recognized
(12). These inflammatory reactions following percutaneous
revascularization procedures are characterized by damage to
endothelial, subendothelial structures, and medial regions,
with rupture of the IEL followed by the recruitment of
inflammatory cells. Inflammatory cells induce release of
growth factors and cytokines, which are potent mitogens
for SMC migration and proliferation, possibly leading to
restenosis. It has been shown that TNF-alpha and
interleukin-1 (IL-1) are actively involved in the process of
inflammation and that neointimal formation is associated
with increased endothelial and SMC fibronectin synthesis
induced by TNF-alpha and IL-1 after an immune inflam-
matory reaction (13–16). All of these processes are mediated
by adhesion molecules, including P-selectin, which is the
initial stimulus to leukocyte recruitment to the endothelium.
Figure 2. Photomicrographs of porcine coronary arteries 28 days after injury (Movat staining, 2.53). (A) Representative light microscopy cross section of
injured coronary artery from recombinant P-selectin glycoprotein ligand-immunoglobulin group, showing reduced neointimal hyperplasia with larger
luminal area. (B) Representative light microscopy cross section of injured coronary artery from the placebo group, showing extensive neointimal hyperplasia
with smaller luminal area. L 5 lumen. N 5 neointima, M 5 media.
Figure 3. Immunohistochemical photomicrographs of porcine coronary arteries 28 days after injury (403). Brown stain denotes presence of tumor necrosis
factor-alpha (TNF-alpha), interleukin (IL)-1 beta, and proliferating cell nuclear antigen (PCNA). (A) TNF-alpha immunostaining of injured coronary
artery from recombinant P-selectin glycoprotein ligand-immunoglobulin (rPSGL-Ig) group. (B) TNF-alpha immunostaining of injured coronary artery
from the placebo group. (C) IL-1 beta immunostaining of injured coronary artery from rPSGL-Ig group. (D) IL-1 beta immunostaining of injured coronary
artery from the placebo group. (E) PCNA immunostaining of injured coronary artery from rPSGL-Ig group. (F) PCNA immunostaining of injured
coronary artery from the placebo group.
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The physiological ligand for P-selectin is PSGL-1, and it
serves as the only high-affinity counter-receptor for
P-selectin (17). It has been demonstrated that P-selectin
expression on the endothelial surface is markedly upregu-
lated following vessel injury and is associated with increased
inflammatory cell adherence to coronary artery endothelium
(18). Administration of a monoclonal antibody to P-selectin
significantly attenuated inflammatory cell accumulation and
endothelial dysfunction (18). Ikeda et al. (19) reported that
treatment with sialyl Lewisx-containing oligosaccharide
(Slex-OS) suppressed P-selectin expression and inhibited
the recruitment and accumulation of platelets and leuko-
cytes on the damaged endothelium in a canine thrombosis
model. This finding was supported by the study from
Kumar et al. (20), which demonstrated that administration
of rPSGL-Ig in a porcine thrombosis model leads to faster
thrombolysis and reduced reocclusion, probably by prevent-
ing interaction of leukocytes with platelets and the injured
arterial wall.
One explantation, therefore, for the findings of reduced
neointimal hyperplasia in the current study is that
rPSGL-Ig administration abolished the activation of in-
flammatory cells after vessel injury, thus decreasing the
release of inflammatory cytokines. In our study, local tissue
level of the inflammatory mediators TNF-alpha and IL-1
beta as well as macrophage infiltration, were decreased by
rPSGL-Ig treatment. Both TNF-alpha and IL-1 beta
appear to play a pivotal role in the development of vascular
stenosis following vessel injury (21,22). It has been reported
that neutralization of TNF-alpha activity in a rabbit model
reduced the severity of coronary artery lesions, which was
associated with less inflammation and decreased accumula-
tion of fibronectin in the vessel wall (13).
The inflammatory response induced by percutaneous
transluminal revascularization is characterized by disruption
of endothelial and subendothelial structures. Dysfunctional
coronary endothelial cells will exhibit decreased basal nitric
oxide (NO) release and promote further adhesion of
leukocytes through the CD11b/CD18 mechanism. The
restoration of NO release through adenovirus-mediated NO
synthase transfer and NO donors has been demonstrated to
significantly reduce neointimal formation after vessel injury
in different animal models (23–27). It has been shown that
restored NO production inhibited cytokine-induced endo-
thelial expression of vascular selectins, decreased adhesion,
migration, and activation of inflammatory cells, and reduced
vascular SMC migration and proliferation (27–32).
rPSGL-Ig has been shown to preserve the morphological
integrity and function of the endothelium through the
inhibition of leukocyte-endothelial cell interaction (33),
thus potentially maintaining NO release. Gries et al. (34)
recently reported that NO inhibits P-selectin expression and
platelet aggregation both in vitro and in vivo. Thus, reduced
neointimal formation found in the rPSGL-Ig group of the
current study may relate in part to preserved endothelial
integrity due to antagonism of P-selectin and maintained
NO release. This mechanism is supported by recent kidney
ischemia/reperfusion injury studies by Takada et al. (35,36).
In these studies, a P-selectin inhibition-mediated decrease
in leukocyte accumulation of reperfused ischemic rat kid-
neys resulted in a reduction of inflammatory cytokine
message and in suppression of the elevated endothelin
message found in nontreated control animals.
Study limitations. This study has several limitations. First,
the most appropriate control for rPSGL-Ig is somewhat
problematic. The “ideal” control would be a nonactive
(nonfucosylated) chimera. This reagent has proven to be
very difficult to produce because the activity of the “control”
material is quite variable from batch to batch, with some
batches as active as the rPSGL-Ig. The sponsor is unable to
produce sufficient quantities of inactive reagent for large
animal studies. Moreover, studies with the low-activity form
of rPSGL-Ig have demonstrated results similar to those
with saline control (33,37–39). A IgG1 isotype control
would be even less suitable because it would not reflect the
mutations in the rPSGL-Ig chimera that prevent it from
binding the Fc receptor or fixing complement, nor would it
represent the rPSGL portion of the molecule. Therefore, we
believe that the overall interpretation of the data and the
value of our observations are not severely limited by the use
of the saline control group.
Second, we did not directly assess the effect of rPSGL-Ig
in the injured vessel segments. However, other investigators
have demonstrated (8) that P-selectin was upregulated in rat
carotid arteries after balloon injury. Third, we observed
abundant PCNA staining in control vessels 28 days after
injury, whereas some prior studies have suggested that
cellular proliferation is no longer apparent 14 days after
injury. The explanation for this variation between ours and
others is unknown, but we did use appropriate positive and
negative controls for PCNA staining, and the results were
reproducible in our laboratory.
Fourth, another limitation of this study was the use of
injury to a normal porcine coronary artery rather than
balloon dilation of a pre-existing coronary lesion, which
more accurately resembles the human scenario with regard
to the coronary disease process of inflammatory cell infil-
tration and cytokine expression. However, it should be
noted that the post-injury response of this model did result
in both infiltration of inflammatory cells and cytokine
expression with distinct histopathological similarities to
human restenosis, including a prominent inflammatory and
cytokine response. The extrapolation of the findings of a
restenotic study from any animal models should be made
with caution because no single model has yet been shown to
reliably predict restenosis in humans. Animals studies may,
however, help to further the understanding of the patho-
physiology of the human disease process.
Conclusions. Antagonism of P-selectin using rPSGL-Ig
decreases the intimal hyperplasia and results in increased
vessel luminal diameter after balloon injury in the porcine
coronary model. The findings of this study suggest a pivotal
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role of P-selectin-mediated inflammation in the pathogen-
esis of restenosis.
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